Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytoGenix has received a notice of allowance for a patent on its original single stranded DNA expression plasmid vectors in Australia. The patent claims both compositions and methods for using the single stranded DNA expression vectors.
Subscribe to our email newsletter
The subject matter includes several variations of the expression vector system for inducing cells to produce specifically designed single strands of DNA (ssDNA) which may be used in antisense, aptamer, triplex or DNA enzyme applications. Cytogenix said that the claimed system provides a more advanced and flexible approach for using the company’s proprietary ssDNA expression system.
Malcolm Skolnick, CytoGenix president and CEO, said: “The award of this allowance provides further validation of CytoGenix technology and improves the company’s ability to secure strategic partners that can assist in commercialization of CytoGenix products using this ssDNA expression system.”